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Abstract
Background: Mycoplasma synoviae causes infectious synovitis and respiratory diseases in chickens and turkeys
and may lead to egg shell apex abnormalities in chickens; hence possesses high economic impact on the poultry
industry. Control of the disease consists of eradication, vaccination or medication. The aim of the present study
was to determine the in vitro susceptibility to 14 different antibiotics and an antibiotic combination of M. synoviae
strains originating from Hungary and other countries of Central and Eastern Europe.
Results: Minimal inhibitory concentration (MIC) values of a total of 41 M. synoviae strains were determined by
the microbroth dilution method. The strains were collected between 2002 and 2016 and originated from Hungary
(n = 26), Austria (n = 3), the Czech Republic (n = 3), Slovenia (n = 3), Ukraine (n = 3), Russia (n = 2) and Serbia (n = 1).
Tetracyclines (with MIC50 values of 0.078 μg/ml, ≤0.25 μg/ml and 0.5 μg/ml for doxycycline, oxytetracycline and
chlortetracycline, respectively), macrolides (with MIC50 values of ≤0.25 μg/ml for tylvalosin, tylosin and tilmicosin),
pleuromutilins (with MIC50 values of 0.078 μg/ml and ≤0.039 μg/ml for tiamulin and valnemulin) and the
combination of lincomycin and spectinomycin (MIC50 1 μg/ml (0.333/0.667 μg/ml)) were found to be the most
effective antibiotic agents against M. synoviae in vitro. High MIC values were detected in numerous strains for
fluoroquinolones (with MIC50 values of 1.25 μg/ml and 2.5 μg/ml for enrofloxacin and difloxacin), neomycin
(MIC50 32 μg/ml), spectinomycin (MIC50 2 μg/ml), lincomycin (MIC50 0.5 μg/ml) and florfenicol (MIC50 4 μg/ml).
Nevertheless, strains with elevated MIC values were detected for most of the applied antibiotics.
Conclusions: In the medical control of M. synoviae infections the preliminary in vitro antibiotic susceptibility testing
and the careful evaluation of the data are crucial. Based on the in vitro examinations doxycycline, oxytetracycline,
tylvalosin, tylosin and pleuromutilins could be recommended for the therapy of M. synoviae infections in the region.
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Background
Mycoplasma synoviae is a cell wall-less pathogen which
has significant economical impact in the poultry industry
[1]. Clinical signs caused by this bacterium comprise
synovitis and respiratory diseases in chickens and tur-
keys, and mainly in commercial egg layers the reduction
of egg production and hatchability, and egg shell apex
abnormalities [2]. The severity of the clinical signs may
vary from sub-clinical to severe forms and is aggravated
by the presence of other pathogens (e.g. infectious bron-
chitis virus, Newcastle disease virus, influenza A virus,
Escherichia coli or other mycoplasmas) and inadequate
housing conditions [3, 4].
The three main approaches for the control of the
disease are eradication followed by prevention, vaccin-
ation or medication. While eradication and vaccination
provide long-term solution for the control of mycoplas-
mosis, medication can be a prompt and effective tool to
reduce the economic losses by mitigating egg transmission
and clinical signs [1]. However, antibiotic susceptibility
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profile should first be determined to maximize treatment
efficacy [5].
Due to their cell wall-less characteristic mycoplasmas
are readily resistant to ß-lactam antibiotics and as they
do not synthesize folic acid sulphonamides, sulfones or
trimethoprim are ineffective against these pathogens also
[6]. Natural resistance to erythromycin and other 14-
membered ring macrolides was described in M. synoviae
[7]. Mycoplasmas showed susceptibility to tetracyclines,
fluoroquinolones and macrolides both in vitro and in
vivo, and the efficacy of tiamulin and the combination of
lincomycin and spectinomycin against M. synoviae
under experimental conditions had been proved long
before [5, 7–14]. In vitro determination of antibiotic
susceptibility of M. synoviae is an essential tool for the
choice of the appropriate antibiotic agent in the therapy
with taking in consideration the factors which may influ-
ence the antimicrobial effect in vivo (e.g. biofilm synthe-
sis) [15]. However, the performance of the in vitro tests
in the case of mycoplasmas is time-consuming and
requires special techniques, thus usually it is not car-
ried out in routine diagnostics and comparable data
about the antibiotic susceptibility of M. synoviae
strains originating from Europe are scarce in the lit-
erature also [5, 7, 13, 16, 17].
In the present study the antibiotic susceptibility profile
of M. synoviae strains originating from Central and
Eastern Europe was determined by microbroth dilution
method in the case of antibiotics commonly used in vet-
erinary practice and which have potential to be used
against avian mycoplasmosis.
Methods
M. synoviae strains were isolated from trachea swabs
collected from turkeys and chickens originating from the
Central and Eastern European region between 2014 and
2016. Production phase of the sampled chickens varied
among breeders, commercial layers and broilers, while
only meat-type turkeys were examined in the study
(Table 1). Ethical approval and specific permission were
not required for the study as all samples were collected
by the authors during routine diagnostic examinations
or necropsies with the consent of the owners. Trachea
swabs were washed in 2 ml modified Frey’s broth
medium [18] and incubated at 37 °C with 5% CO2 at-
mosphere. The broth medium consisted of 0.225 g/ml
Frey Mycoplasma broth base, 20% porcine serum, 0.01%
NAD, 0.01% cysteine, 200 IU/ml penicillin G, 0.5% glu-
cose, 0.5% pyruvate and 0.005% phenol red in distilled
water; all products originated from Sigma-Aldrich,
Germany. Strains were gained after one-time filter clon-
ing, minimizing the in vitro mutations of the isolates.
The QIAamp DNA Mini Kit (Qiagen Inc., Hilden,
Germany) was used for DNA extraction according to the
manufacturers’ instructions for Gram-negative bacteria.
The purity of the cultures was confirmed by a universal
Mycoplasma PCR system targeting the 16S/23S rRNA
intergenic spacer region in Mycoplasmatales [19]
followed by sequencing on an ABI Prism 3100 auto-
mated DNA sequencer (Applied Biosystems, Foster City,
CA), sequence analysis and BLAST search. Out of a total
of 41 M. synoviae strains tested in the study 26 strains
originated from Hungary, three strains each from
Austria, the Czech Republic and from Ukraine, two
strains from Russia and one from Serbia (Table 1). Also,
three strains isolated in Slovenia between 2002 and 2008
were included in the study. The number of colour chan-
ging units (CCU) was calculated by microbroth dilution
method, from the highest dilution showing colour
change (red to yellow shift) after two weeks of incuba-
tion [20].
The following antimicrobial agents were examined
during the microbroth dilution tests: the fluoroquino-
lones: enrofloxacin and difloxacin; the aminocyclitol:
spectinomycin; the aminoglycoside: neomycin; the linco-
samide: lincomycin; the tetracyclines: doxycycline,
oxytetracycline and chlortetracycline; the macrolides:
tylosin and tilmicosin; the pleuromutilins: tiamulin and
valnemulin; and the amphenicol: florfenicol; all products
originated from VETRANAL, Sigma-Aldrich, Germany.
Lincomycin and spectinomycin were applied in combin-
ation as well, in a ratio of 1:2. The macrolide tylvalosin
(Aivlosin, ECO Animal Health Ltd., UK) was also in-
cluded in the examinations. The antibiotics were diluted
and stored according to the recommendations of
Hannan [20]. Stock solutions of 1 mg/ml fluoroquino-
lones were prepared in 0.1 M NaOH; stock solution of
1 mg/ml florfenicol was prepared in 96% ethanol and in
sterile distilled water; and the rest of the stock solutions
of 1 mg/ml were prepared in sterile distilled water and
stored at −70 °C. Freshly prepared two-fold dilutions
were used in each microtest after checking the thawed
antibiotic solutions for any visible changes in their
consistency. The concentration range of the antibiotics
was selected to cover values previously suggested to re-
flect susceptibility, intermediate susceptibility or resist-
ance to the tested agents or which were used in previous
publications (Table 2), in details: 0.039–10 μg/ml for
fluoroquinolones, doxycycline and pleuromutilins, 0.25–
64 μg/ml for neomycin, spectinomycin, lincomycin,
oxytetracycline, chlortetracycline and macrolides, 0.125–
32 μg/ml for florfenicol and 0.25–64 μg/ml (0.083/
0.167–21.333/42.666 μg/ml) for the combination of lin-
comycin and spectinomycin.
Microbroth dilution examinations were performed
according to Hannan [20] on 104–105 CCU/ml of the
strains. In brief, the tests were performed in 96-well
microtiter plates containing modified Frey’s broth
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medium, using growth controls (broth medium
without antibiotic), sterility controls (broth medium
without antibiotic and Mycoplasma inoculum), pH
controls (broth medium adjusted to pH 6.8) and
quality controls (the duplicate of the M. synoviae type
strain WVU 1853, NCTC 10124). All strains were
tested in duplicates.
The minimum inhibitory concentrations (MIC)
were determined from the lowest concentration of
the antibiotics where no pH and colour change of
the broth was detected, meaning that the growth of
the bacteria was completely inhibited in the broth.
Initial MIC values were determined when the growth
controls showed colour change. Final MIC values
were determined when no further growth was de-
tected, generally after two weeks of incubation.
MIC50 and MIC90 values were defined as the lowest
concentrations that inhibited the growth of 50% or
90% of the strains [20].
Results
The quality control type strain (WVU 1853, NCTC
10124) showed consistent results throughout the
study and the data (Table 2) were in accordance with
previously recorded MIC values gained by microbroth
dilution method: ranges of initial MIC values were
0.125–0.5 μg/ml for enrofloxacin and difloxacin, 0.1–
0.125 μg/ml for oxytetracycline, ≤0.015 μg/ml for
doxycycline, 0.025–0.06 μg/ml for tylosin, 0.015–
0.06 μg/ml for tilmicosin, and ≤0.03–0.1 μg/ml for
tiamulin before [5, 7, 13, 17]. Currently, there are no
comparable MIC values available in the case of the
M. synoviae type strain (WVU 1853, NCTC 10124)
for the rest of the antibiotics tested in the present
study. The ranges of the initial and final MIC values,
MIC50 and MIC90 values for each antibiotic and for
the combination are included in Table 2. In the cases
of four antibiotics (oxytetracycline, chlortetracycline,
neomycin and lincomycin) at least four-fold difference
Table 2 Summary of MIC range, MIC50 and MIC90 values (μg/ml) of the isolated Mycoplasma synoviae strains with the suggested
non-official breakpoints (in μg/ml; S: susceptible, R: resistant) and MIC values for the type strain WVU1853
Non-official
breakpoints
WVU1853
initial
WVU1853
final
Range initial Range final MIC50
initial
MIC50
final
MIC90
initial
MIC90
final
Fluoroquinolones
Enrofloxacin S ≤ 0.5; R≥ 2 [5] 0.312 1.25 0.312 – >10 0.312 – >10 1.25 1.25 >10 >10
Difloxacin S ≤ 0.5; R≥ 4 [5] 1.25–2.5 1.25–2.5 0.625 – >10 0.625 – >10 2.5 2.5 10 >10
Aminocyclitol
Spectinomycin S ≤ 2; R > 4 [28] 2 8 ≤0.25–8 1–16 2 2 4 8
Aminoglycoside
Neomycin S ≤ 4; R > 4 [25] 64 – >64 >64 4 – >64 8 – >64 32 >64 >64 >64
Lincosamide
Lincomycin S ≤ 2; R≥ 8 [43] 0.5 0.5 ≤0.25 – >64 ≤0.25 – >64 0.5 1 1 4
Tetracyclines
Doxycycline S ≤ 4; R≥ 16 [25] ≤0.039 0.156 ≤0.039–0.312 0.078–1.25 0.078 0.156 0.312 0.625
Oxytetracycline S ≤ 4; R ≥ 16 [5] ≤0.25 0.5 ≤0.25–1 ≤0.25–8 ≤0.25 1 1 4
Chlortetracycline S ≤ 4; R ≥ 16 [25] 0.5 1 ≤0.25–8 ≤0.25–16 0.5 2 2 8
Macrolides
Tylosin S ≤ 1; R ≥ 4 [5] ≤0.25 ≤0.25 ≤0.25–2 ≤0.25–8 ≤0.25 ≤0.25 ≤0.25 ≤0.25
Tilmicosin S ≤ 8; R≥ 32 [5] ≤0.25 ≤0.25 ≤0.25–64 ≤0.25 – >64 ≤0.25 ≤0.25 1 2
Tylvalosin S ≤ 0.5; R > 2 [28] ≤0.25 ≤0.25 ≤0.25–0.5 ≤0.25–1 ≤0.25 ≤0.25 ≤0.25 ≤0.25
Pleuromutilins
Tiamulin S ≤ 8; R ≥ 16 [7] 0.078 0.078 ≤0.039–0.625 0.078–1.25 0.078 0.156 0.312 0.312
Valnemulin S ≤ 0.125;
R > 0.125 [25]
≤0.039 ≤0.039 ≤0.039 ≤0.039 ≤0.039 ≤0.039 ≤0.039 ≤0.039
Amphenicol
Florfenicol S ≤ 2; R ≥ 8 [25] 1–2 1–4 0.5–8 1–16 4 8 8 8
Combination
Lincomycin:
Spectinomycin
S ≤ 2(0.666/1.334);
R > 4(1.332/2.668) [25]
1
(0.333/0.667)
1–2
(0.333/0.667–
0.666/1.334)
0.5–2
(0.167/0.333–
0.666/1.334)
0.5–4
(0.167/0.333–
1.332/2.668)
1
(0.333/0.667)
1
(0.333/0.667)
2
(0.666/1.334)
2
(0.666/1.334)
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was observed in the MIC50 or MIC90 values when
initial and final MIC values were compared (Tables 1
and 2 and Additional file 1). The initial MIC values
are evaluated and discussed throughout the study
[20]. The MIC50 values of the strains originating from
different countries of the Central and Eastern
European region showed high similarity, thus if other-
wise not indicated the MIC values of all examined
strains are evaluated together.
The distribution of the MIC values for enrofloxacin
showed two main peaks (Fig. 1a1), while predominantly
even distribution of the MIC values for difloxacin was
observed (Fig. 1a2). Among the Hungarian strains the
MIC50 values for enrofloxacin of the isolates originating
from chickens (10 μg/ml, n = 11) was notably higher
than of the strains originating from turkeys (1.25 μg/ml,
n = 15), which corresponds to the observed two-peaked
distribution (Fig. 1a2). In this comparison, four-fold dif-
ference was detected between the MIC50 values for
difloxacin (with MIC50 1.25 μg/ml and 5 μg/ml of strains
from turkeys and chickens, respectively) and the distri-
bution of the MIC values for this agent differed remark-
ably according to the isolates’ host of origin (Fig. 1b2).
No outlier strains with high MIC values were observed
for the tetracyclines doxycycline, oxytetracycline and
chlortetracycline (Fig. 1c, d and e). The strains generally
showed low MIC values for the three examined macro-
lides (Fig. 1f, g and h), with the exception of one strain
(MYCAV 185), especially in the case of tilmicosin (MIC
64 μg/ml). Strain MYCAV 185 was isolated from a back-
yard flock, where excess antibiotic usage was docu-
mented, and it showed elevated MIC values for most
antibiotics tested. High MIC values were detected for
neomycin in most strains (Fig. 1i), especially after two
weeks of incubation (final MIC50 > 64 μg/ml, Table 2 and
Additional file 1). The majority of the strains’ MIC
values for spectinomycin and for lincomycin distributed
around the MIC50 values (Fig. 1j and k). Outlier strains
were detected for both antibiotics; one strain with low
MIC value in the case of spectinomycin (MYCAV 197),
and one with high MIC value in the case of lincomycin
(MYCAV 185). When lincomycin and spectinomycin
were applied in combination, the range of the MIC
values slightly tightened, no outlier strains were de-
tected and lower concentration of the individual anti-
biotics was sufficient in the combination to inhibit
the growth of 50% of the strains (Fig. 1j, k and l).
Pleuromutilins showed high efficacy against the M.
synoviae strains (Fig. 1m and n). No growth was ob-
served in the presence of valnemulin and most strains
were inhibited at the MIC50 concentration of tiamu-
lin. The MIC values of the majority of the strains
grouped around the MIC50 value (4 μg/ml) in the
case of florfenicol also (Fig. 1o).
Discussion
Conventional methods for the determination of anti-
biotic susceptibility of mycoplasmas is time-consuming,
laborious and requires special techniques, thus it is not
performed routinely [20]. Moreover, the interpretation
of the results is hampered by the lack of official stan-
dards. In the case of human pathogen mycoplasmas the
Clinical and Laboratory Standards Institute (CLSI) has
provided official breakpoints for certain antibiotics [21].
However, given the fastidious nature and inherent differ-
ences in the cultivation of these pathogens, procedures
and media vary according to each of the examined spe-
cies [22]. Initiations to establish standard CLSI protocols
for mycoplasmas with veterinary relevance have been
made, but for the time being the recommendations of
Hannan [20] are supposed to be applied in these cases
[23]. In the lack of official breakpoints, the data of the
present study are interpreted according to values previ-
ously used in other publications [5, 7, 13, 20, 24] or to
breakpoints of other avian pathogens determined by the
CLSI [25] (Table 2).
Susceptibility (MIC ≤0.5 μg/ml according to Landman
et al. [5]) and also resistance (MICs ≥2 or 4 μg/ml for
enrofloxacin or difloxacin, respectively) [5] to fluoroqui-
nolones have been described in M. synoviae strains be-
fore [5, 12, 16, 17, 24]. Differences in the antibiotic
usage and density of poultry flocks were assumed to be
responsible for the observed variations [17] and resist-
ance to fluoroquinolones was described in Europe [5]. In
the present study, elevated MIC values of fluoroquino-
lones were observed regardless of the strains’ geograph-
ical origin. On the other hand, MIC values showed
correlation with the host of origin, most probably in
connection with the length of the hosts’ production
cycle. In the interpretation of Landman et al. [5], more
than half of the Hungarian strains isolated from
chickens (mainly breeders and layers) were regarded
resistant to enrofloxacin (MIC ≥2 μg/ml) and difloxa-
cin (MIC ≥4 μg/ml), while most of the strains from
meat-type turkeys (short life production cycle) were
considered susceptible or intermediately susceptible to
these antibiotics.
The MIC values of tetracyclines also varied in pre-
vious works according to the strains’ country of ori-
gin, with most European strains showing susceptibility
(MIC ≤4 μg/ml) [20] to these agents [5, 12, 13, 16].
In accordance with previous studies, all strains in-
cluded in the current study showed high susceptibility
to doxycycline and oxytetracycline, and chlortetracyc-
line proved to be highly efficient at least against 90%
of the strains.
The 16-membered ring macrolides showed good in
vitro activity against M. synoviae strains all over the
world previously [5, 12, 14, 16, 26–30], but field strains
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showing intermediate susceptibility or resistance (MIC
>1 μg/ml according to Hannan [20]) have been isolated
also, even from Europe [13]. In avian Mycoplasma
strains resistance to tilmicosin developed more readily
and quicker than to tylosin under laboratory conditions
[31]. Several previous studies reported the slow increase
of resistance to tylosin in M. synoviae and M. gallisepti-
cum in vitro also [7, 32, 33]. In the current examination,
the majority of the strains were inhibited by low concen-
trations of tylvalosin and tylosin, and 90% of the strains
were susceptible to tilmicosin (≤1 μg/ml) [5], confirming
the high in vitro efficiency of these macrolides against
M. synoviae. Elevated MIC values were detected primar-
ily in the case of tilmicosin (with four strains reaching
MIC >1 μg/ml), which is concordant with previous
observations in vitro [31], and assumes the more rapid
development of resistance against this agent.
Lincosamides have similar protein synthesis inhibitory
mechanism on the 50S subunit of the bacterial ribosome
as macrolides [34], and lincomycin was found to be
efficacious against avian mycoplasmas before [3, 16].
Cross-resistance was described between macrolides and
lincosamides and it was associated with mutations in the
23S ribosomal RNA of M. synoviae [35]. In the current
study, all isolates showed susceptibility (≤2 μg/ml) [20]
to lincomycin except for one outlier strain (MYCAV
185; MIC >64 μg/ml), which showed elevated MIC
values to macrolides as well.
Aminoglycosides and aminocyclitols are most com-
monly administered for the treatment of bacterial enter-
itis in poultry [36, 37], and by the oral application these
compounds absorb poorly from the gastrointestinal tract
[38]. Previous in vitro examinations on the efficacy of
neomycin against M. synoviae revealed that high con-
centrations of the antibiotic were needed for the inhib-
ition of the pathogen (MICs 32–128 μg/ml) [30]. On the
other hand, spectinomycin proved to be effective against
the French and Iranian M. synoviae strains in vitro with
MIC values below the susceptibility breakpoint of 4 μg/
ml (according to CLSI [25]) [16, 28]. Potentially lower
concentrations of spectinomycin were sufficient for the
inhibition of the growth of M. synoviae when it was ap-
plied in combination with lincomycin [28], and this
a1 a2
b1 b2
c d
e f
g h
i j
k l
m n
o
Fig. 1 MIC50 values are marked with asterisks. MIC values of 41 M.
synoviae strains are demonstrated to enrofloxacin (a1), difloxacin
(b1), doxycycline (c), oxytetracycline (d), chlortetracycline (e), tylosin
(f), tilmicosin (g), tylvalosin (h), neomycin (i), spectinomycin (j),
lincomycin (k), the combination of lincomycin and spectinomycin (l),
tiamulin (m), valnemulin (n) and florfenicol (o). The MIC values for
enrofloxacin (a2) and difloxacin (b2) of isolates originating from
Hungary from meat-type turkeys (white columns; n = 15) and mostly
breeder and layer chickens (grey columns; n = 11) are presented in
individual diagrams also
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combination successfully controlled experimental M.
synoviae infection in vivo before [9]. In the present
study, the majority of the strains showed resistance to
neomycin (MIC >4 μg/ml according to CLSI [25]) but
were inhibited by spectinomycin at concentrations below
the assumed breakpoint (MIC ≤4 μg/ml [25]). The com-
bination of lincomycin with spectinomycin improved the
efficacy of both antibiotics against most M. synoviae
strains (Tables 1 and 2 and Additional file 1); therefore
the use of their combination is supposed to be preferable
in the therapy.
Pleuromutilins showed high in vitro effect against
avian mycoplasmas before [7, 13] and have been used
in the treatment of mycoplasmosis in poultry [39].
Resistance against these substances in M. gallisepti-
cum and M. synoviae develops gradually [7], as only
one mutation is enough for the elevation of MIC
values, but to achieve high level resistance the com-
bination of multiple mutations is required [39]. The
M. synoviae strains examined in this study showed
high susceptibility to tiamulin and valnemulin, assum-
ing their potential in the therapy.
Phenicols are broad-spectrum antibiotics and showed
in vitro activity against certain mycoplasmas before
[23, 30, 38, 40]. In the present study, although two
strains were inhibited by lower concentrations of flor-
fenicol (MIC 0.5 μg/ml), narrow range of MICs was ob-
served among the rest of the strains (MICs between 2
and 8 μg/ml), showing lower effectiveness of florfenicol
against M. synoviae than reported in other studies or in
M. gallisepticum [30, 40].
The observed differences between the initial and
final MIC values of the mycoplasmastatic antibiotics
chlortetracycline and lincomycin [34] lead to the re-
categorization of certain strains from susceptible to
resistant during the interpretation of the results, while
in other cases no difference was detected at all. Also,
remarkable deviation of the MIC values for neomycin
(which has concentration-dependent mycoplasmacidal
effect [34]) was observed when initial and final read-
ings were compared, although it did not alter signifi-
cantly the interpretation of the data. Many factors
may influence the growth of the bacteria in the in
vitro tests; the discrepancies may indicate the inacti-
vation of the used antibiotics during incubation, or
the presence of a slower growing minor population
which may have significance in the determination of of-
ficial breakpoints in the future and in the estimation of
the in vivo efficacy of the antibiotics [20, 24, 26]. The
combined examination of the in vitro tests with
pharmacokinetics/pharmacodynamics studies and in
vivo experiments would probably enable the better un-
derstanding of the importance of the initial and final
MIC values, and the differences in between.
Nevertheless, freshly prepared antibiotic solutions are
administered during treatment, which minimize the
possibility of antibiotic inactivation and initial MIC
values are evaluated in the standardized methods for
human pathogen mycoplasmas as well [22]; therefore
the initial MIC values are advised to be taken into ac-
count in the interpretation of the results in mycoplas-
mas with veterinary relevance.
Strains originating from the same farm but from dif-
ferent years possessed similar MIC values (e.g. strains
from farms 4, 13 and 14; Table 1). However, apart from
oxytetracycline, doxycycline, tylvalosin, valnemulin and
the combination of lincomycin and spectinomycin,
strains with elevated MIC values were detected in the
cases of all antibiotics tested. Even more, as an alarming
example for irresponsible antibiotic usage, one strain
(MYCAV 185) showed high MIC values to several anti-
biotics, especially to fluoroquinolones, macrolides and to
lincomycin. It is noteworthy, that the combined applica-
tion of lincomycin with spectinomycin remarkably
reduced the inhibitory antibiotic concentration against
this strain (from MIClincomycin > 64 μg/ml to MIClincomy-
cin:spectinomycin 2 μg/ml (0.666/1.334 μg/ml)). All of these
observations highlight the importance of testing the
antibiotic susceptibility of M. synoviae before treatment.
On the other hand, in clinical cases when rapid inter-
vention is needed (e.g. mortality or high morbidity with
severe clinical signs) and the treatment cannot wait for
the results of the time-consuming and laborious in vitro
tests, the presented data may serve as a guide in the
choice of the appropriate antibiotic therapy in the
Central and Eastern European region.
Conclusions
Antibiotic susceptibility testing of M. synoviae is labori-
ous and time-consuming, and is not performed in rou-
tine diagnostics, thus empirical antibiotic treatment is
usually applied by the clinicians. The MIC values of the
41 M. synoviae strains provided in the present study re-
vealed the in vitro effectiveness of tetracyclines, macro-
lides and pleuromutilins, and assume the potential
usefulness of these agents in the therapy of mycoplas-
mosis in poultry in Central and Eastern Europe. How-
ever, elevated MIC values were observed in several
cases during the examinations, which concerns antibi-
otics with importance in human medicine as well (e.g.
fluoroquinolones). In order to preserve these critical
antimicrobials for the therapy of humans, prudent anti-
biotic usage is recommended based on preliminary in
vitro antibiotic susceptibility tests and on the careful
evaluation of these data by considering the difficulties
in the interpretation of the results and the factors influ-
encing antibiotic effectiveness in vivo.
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